Randomized, double-blind, controlled trial of risperidone Versus clozapine in patients with chronic schizophrenia

Journal of Clinical Psychopharmacology

Volumn 15, Issue 1, 1995, Pages 45S-51S

  Klieser, Eckhard ^a   Lehmann, Erlo ^a   Kinzler, Eckardt ^b   Wurthmann, Cornelius ^a   Heinrich, Kurt ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Gerontopsych Abt Klin Flurstrasse   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; RISPERIDONE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0028855094     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/00004714-199502001-00008     Document Type: Article

References (42)

1. Keefe RS, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Kendler KS, Horvath TB, Nora R, Davis KL. Characteristics of very poor outcome in schizophrenia. Am J Psychiatry 1987;144:889–95.
2. Casey DE, Keepers GA. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacol Curr Trends 1988;5:74–93.
3. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;3:67–72.
4. Baldessarini RJ, Frankenburg FR. Clozapine a novel antipsychotic agent. N Engl J Med 1991;324:746–54.
5. Kane JM, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789–96.
6. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992;160[suppl 17]:41–5.
7. Levinson DF. Pharmacological treatment of schizophrenia. Clin Ther 1991;13:326–52.
8. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17:247–61.
9. Hirsch SR, Puri BK. Clozapine progress in treating refractory schizophrenia. BMJ 1993;306:1427–8.
10. 2 antagonism in schizophrenia: clinical, extrapy-ramidal and neuroendocrine response in a preliminary study with risperidone. Hum Psychopharmacol 1990;5:225–31.
11. 2 antagonist risperidone (R64766) in the treatment of chronic psychosis: an open dose-finding study. Schizophr Res 1989;2:411–5.
12. Gelders YG, Heylden SLE, Vanden Bussche G, et al. Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 1990;23:206–11.
13. Meco G, Bedini L, Bonifati V, Sonsini V. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. Curr Ther Res 1989;46:876–83.
14. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients. Psychopharmacology 1989;99:445–9.
15. Borison RL, Pathiraja AP, Diamond BL, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213–8.
16. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double blind comparative study. Acta Psychiatr Scand 1992;85:295–305.
17. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebocontrolled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25–40.
18. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825–35.
19. MUller-Spahn F, the International Risperidone Research Group. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel group study versus haloper-idol. Clin Neuropharmacol 1992;15[suppl 1]:90A–1A.
20. World Health Organization. Mental disorders: glossary and guide to their classification in accordance with the ninth revision of the International Classification of Diseases. Geneva: World Health Organization, 1978.
21. Overall LJ, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799–812.
22. Guy W. Clinical Global Impression. In: Guy W, Ed. ECDEU Assessment Manual for Psychopharmacology (DHEW No. (ADM) 76–338). Rockville: National Institute of Mental Health 1976:218–22.
23. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11–9.
24. Fahndrich E (Ed). In: Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie. Das AMDP System. 3rd ed. Berlin: Springer, 1979.
25. Mertens C. Long-term treatment of chronic schizophrenic patients with risperidone. Schizophr Res 1990;3:48.
26. Mertens C. Long-term experience with risperidone. Presentation at First International Risperidone Investigators Meeting, Paris, France, March 9–10, 1992.
27. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand (in press).
28. Buch DL. Clozapine: a novel antipsychotic. Am Family Phys 1992;45:795–9.
29. 2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685–93.
30. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PM. The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661–70.
31. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:S18–27.
32. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263–87.
33. Gelders YG. Thymosthenic agents, a novel approach in the treatment of schizonhrenia. Br J Psychiatry 1989;155(suppl 5):33–6.
34. Klieser E, Klimke A. Neue Substanzen mit Wirkung auf das Serotoninsystem: In: Heinrich K, Hippius H, Poldinger W, eds. Serotonin-Ein neuer funktioneller Ansatz. Berlin: Springer, 1991.
35. Reyntjens MM, Gelders YG, Hoppenbrouwers M-IJA, et al. Thymosthenic effects of ritanserin (R55667), a centrally acting serotonin S2 receptor blocker. Drug Dev Res 1986;8:205–11.
36. Strauss W, Klieser E. Psychotropic effects of ritanserin. A selective 52 antagonist—an open study. Eur Neuropsychopharmacol 1991;1:101–5.
37. Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 1992;41:494–508.
38. Meert TF, de Haes P, Janssen PM. Risperidone (R64766), a potent and complete LSD antagonist in drug discrimination by rats. Psychooharmacology 1989;97:206–12.
39. Lindström LH. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988;77:524–52.
40. Haller E, Binder L. Clozapine and seizure. Am J Psychiatry 1990;147:1069–71.
41. Naber D, Hippius H. The European experience with use of clozapine. Hosp Commun Psychiatry 1990;41:886–90.
42. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial. Psychopharmacology 1989;99:S60–3.